GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theravance Biopharma Inc (STU:0TB) » Definitions » Cyclically Adjusted Book per Share

Theravance Biopharma (STU:0TB) Cyclically Adjusted Book per Share : €1.94 (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Theravance Biopharma Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Theravance Biopharma's adjusted book value per share for the three months ended in Dec. 2024 was €3.389. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €1.94 for the trailing ten years ended in Dec. 2024.

During the past 12 months, Theravance Biopharma's average Cyclically Adjusted Book Growth Rate was -21.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2025-05-10), Theravance Biopharma's current stock price is €8.70. Theravance Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2024 was €1.94. Theravance Biopharma's Cyclically Adjusted PB Ratio of today is 4.48.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Theravance Biopharma was 5.28. The lowest was 3.03. And the median was 4.15.


Theravance Biopharma Cyclically Adjusted Book per Share Historical Data

The historical data trend for Theravance Biopharma's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theravance Biopharma Cyclically Adjusted Book per Share Chart

Theravance Biopharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 1.96 2.34 1.94

Theravance Biopharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.34 2.53 2.24 1.98 1.94

Competitive Comparison of Theravance Biopharma's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Theravance Biopharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theravance Biopharma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theravance Biopharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Theravance Biopharma's Cyclically Adjusted PB Ratio falls into.


;
;

Theravance Biopharma Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Theravance Biopharma's adjusted Book Value per Share data for the three months ended in Dec. 2024 was:

Adj_Book= Book Value per Share /CPI of Dec. 2024 (Change)*Current CPI (Dec. 2024)
=3.389/133.1571*133.1571
=3.389

Current CPI (Dec. 2024) = 133.1571.

Theravance Biopharma Quarterly Data

Book Value per Share CPI Adj_Book
201503 7.903 99.621 10.563
201506 6.765 100.684 8.947
201509 5.843 100.392 7.750
201512 5.875 99.792 7.839
201603 5.168 100.470 6.849
201606 5.981 101.688 7.832
201609 5.519 101.861 7.215
201612 6.284 101.863 8.215
201703 5.157 102.862 6.676
201706 3.987 103.349 5.137
201709 2.856 104.136 3.652
201712 1.790 104.011 2.292
201803 0.938 105.290 1.186
201806 0.534 106.317 0.669
201809 -0.208 106.507 -0.260
201812 -0.814 105.998 -1.023
201903 -1.786 107.251 -2.217
201906 -2.144 108.070 -2.642
201909 -2.924 108.329 -3.594
201912 -3.533 108.420 -4.339
202003 -2.269 108.902 -2.774
202006 -2.829 108.767 -3.463
202009 -3.472 109.815 -4.210
202012 -3.881 109.897 -4.702
202103 -4.807 111.754 -5.728
202106 -3.393 114.631 -3.941
202109 -3.732 115.734 -4.294
202112 -4.025 117.630 -4.556
202203 -4.194 121.301 -4.604
202206 -4.330 125.017 -4.612
202209 7.205 125.227 7.661
202212 6.394 125.222 6.799
202303 5.717 127.348 5.978
202306 4.816 128.729 4.982
202309 4.538 129.860 4.653
202312 4.061 129.419 4.178
202403 3.881 131.776 3.922
202406 3.678 132.554 3.695
202409 3.402 133.029 3.405
202412 3.389 133.157 3.389

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Theravance Biopharma  (STU:0TB) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Theravance Biopharma's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=8.70/1.94
=4.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Theravance Biopharma was 5.28. The lowest was 3.03. And the median was 4.15.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Theravance Biopharma Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Theravance Biopharma's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Theravance Biopharma Business Description

Industry
Traded in Other Exchanges
Address
901 Gateway Boulevard, South San Francisco, CA, USA, 94080
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Theravance Biopharma Headlines

No Headlines